India’s Top 10 Powerful Influential Pharma Leaders 2016 List
India’s Top 10 Powerful Influential Pharma Leaders 2016 List
Pricing, Regulatory Hurdles & OTC Market remain the key focus at Pharma Leaders 2016 Research Report. Dilip Shanghvi, Pankaj Patel, Samprada Singh, R.C.Juneja, Dilip Surana are among top 10 Powerful Indian Pharma Leaders 2016
Indian Pharmaceutical Industry has evolved as a dominant & powerful sector since india’s seventy years of independence & yet the industry remains largely fragmented with top 100 players in complete command of dominance. Today these top 100 companies have more than 80 % of the market share out of which majority players are domestic companies. MNC’s in india has grown significantly but their growth of late has been outpaced by the aggressive Indian companies. Pharma Leaders, India’s first media to interview more than 500 leaders of the pharmaceutical industry has brought out this special report titled “India’s Top 10 Powerful Pharma Leaders 2016” based on a credible research inputs followed by interviewing & interacting with all the stakeholders of the pharmaceutical industry. The key findings of the report other than the selection of the top 10 Leaders are as the following.
Using comprehensive interview, survey, and observational data from 100 successful Pharma Leaders using the competitive market analysis, the researchers found that our findings on the top 10 influential Powerful Pharma Leaders of 2016 — defined as aggressiveness, assertiveness, and confidence — were also able to “excel in tough conditions considered very risky”.
- Indian Players are likely to dominate the market till 2025
- Top 100 Domestic Players may join hands together through co-marketing, R&D & brand acquisitions.
- Top privately held companies will go for public (IPO) in next 2 years, till 2018
- Top Brands will be up for grabs with premium
- Generics will be the key drivers for growth
- Top 100 companies will set up manufacturing facilities to fuel growth engines.
- Second generation Leaders will take over the Leadership Mantles.
- OTC segments will be the part of top 40 companies out of 100.
- Field Force of top 30 Companies will double by 2018.
- Exports will be the key focus.
India’s Top 10 Powerful Pharma Leaders 2016
There are many organizations who are involved in rankings based purely on turnovers or profits or purely on financial background. While Pharma Leaders research desk purely respects the mechanism of selection process & the judging criteria, we have given considerable emphasis on the trust & branding factors & the credible face of the leadership steering the company’s growth engine & putting patients first. In this feature survey, we have only taken the Indian companies & not included the MNC’s as the scope of the study research involved included the role of visionary leadership, team buildings, brand buildings, CSR & Indian perspective of looking leadership. Network 7 Media Group, the research wing of Pharma Leaders undertook the responsibilities of finding the top 10 Powerful Pharma Leaders of 2016.
The primary objective that our experts looked at is Brand Equity & Leadership Dominance. Indian pharma market is dominated by a strong patronage of brands by the different stakeholders; the research paper looked into great details as how the person concerned has been able to influence the society & industry at large. Corporate Social Responsibilities (CSR) also was one of the top focus while determining the leadership role of the top 10 influential Pharma Leaders of 2016.
Selection Process & Methodology
Unlike other organizations, Pharma Leaders being a media house relied purely on the external patronage & opinions of the key stakeholders on determining the top 10 Leaders.The sample size of the analysis included all 29 states & 7 Union territories, both urban & rural areas on a pan india basis. More than 5000 opinion makers were consulted which included the followings.
- Contemporary Peers
- Past Leadership
- Distribution Agents
- Policy Makers
- Govt Agencies
- Image Consultants
- Medical Representatives
- Market Research Analysts
The Top 10 List
- Dilip Shanghvi,MD,Sun Pharmaceutical Industries Ltd
- Desh Bandhu Gupta, Chairman, Lupin Limited
- Kallam Satish Reddy,Chairman,Dr. Reddy’s Laboratories Ltd
- Y.K. Hamied,Non-Executive Chairman,Cipla Ltd
- Pankaj R. Patel,Chairman & Managing Director,Zydus Cadila
- Glenn Saldanha, CMD, Glenmark Pharmaceuticals Ltd
- Samprada Singh, Chairman Emeritus,Alkem Labs Ltd
- Dilip Surana, CMD, Microlabs Ltd
- R.C.Juneja, Chairman, Mankind Pharma Ltd
- Habil. F.Khorakiwal, Chairman, Wockhardt Ltd
The current market capitalisation of Glenmark stands at Rs 26,152.76 crore.
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Ltd. since 2001. Mr. Saldanha serves as the Chief Executive Officer of Glenmark Pharmaceuticals S.A. He has worked for Eli Lilly in the U.S and was a Management Consultant with Price Waterhouse Coopers. His Services have been used by Smithkline Beecham, Rhone Poulenc Rhorer, Astra, Merck and Johnson and Johnson, among others. He has 15 years of experience in Pharmaceutical Industry. He has been the Chairman of Glenmark Pharmaceuticals Ltd. since May 10, 2011. Mr. Saldanha served as Chairman of Glenmark Generics Ltd. He has been a Director of Glenmark Pharmaceuticals S.A. since 1998. He served as Independent Director of Talwalkars Better Value Fitness Ltd. since October 2009 until November 22, 2011. He was awarded the Watumall Foundation Award for overall excellence. Mr. Saldanha holds a B.Pharm. from Bombay University and an MBA from New York University’s Leonard N.Stern School of Business (US).
Glenmark Pharmaceuticals S.A operates as a pharmaceutical research and development company. It engages in clinical and non-clinical development of the group’s new chemical entity programs. The company’s products include Oglemilast, a PDE-4 inhibitor for asthma; GRC 8200, a DPP-4 inhibitor for diabetes; GBR 401, an anti-CD19 monoclonal antibody; CB-1 antagonist for obesity; and GBR 500, a therapeutic monoclonal antibody for chronic autoimmune disorders. The company has a strategic global collaboration with Sanofi. The company was founded in 2004 and is based in Neuchâtel, Switzerland. Glenmark Pharmaceuticals S.A operates as a subsidiary of Glenmark Pharmaceuticals, Ltd.